StockWatch
·

POLY MEDICURE LTD. Q2 FY27 Results

POLYMEDQ2 FY27 Results
Filing
Result:Very Good· Market: Flat#One-off hit

Outlook: Optimistic · Guidance: Raised

MetricValue (₹ Cr)Q1 FY27Q2 FY26
Revenue580.5310.5%30.8%
Total Income599.537.3%25.5%
Expenditure485.169.5%35.9%
PBT123.947.1%2.7%
Net Profit95.1311.6%3.6%
OPM25.34%1.53pp0.50pp
NPM15.87%0.61pp3.34pp
EPS9.3810.5%3.5%
View full financials

Core revenue grew a strong 30.8% YoY with OPM% broadly steady (25.3% vs 25.8%), but reported PAT growth was muted to 3.6% mainly because other income fell sharply (₹33.9cr → ₹19.0cr), not due to core margin erosion.

POLY MEDICURE LTD. · Q2 FY2027 · THE VERDICT

Revenue Boom, Profit Lag — Can Poly Restore Growth?

Consolidated revenue surged 30.8% to ₹580.5 Cr, but PAT crawled 3.6% to ₹95.1 Cr — a 27-point gap driven by inventory reversal, acquisition drag, and cost headwinds. The call reveals a normalized EBITDA margin of 25.3%, but management's margin-recovery timeline now stretches into FY28–FY29.

11 Nov 2026 · 6 min read
Reported Q2 PAT

₹95.1 Cr

+3.6% YoY

Q2 EBITDA margin

25.3%

normalized; acquisition drag embedded

Revenue-to-PAT gap

27 pp

+30.8% vs +3.6% growth

Domestic growth

22%

beating 20% guidance

On paper, Poly delivered a blowout quarter: ₹580.5 Cr in consolidated revenue, up 31% from a year ago. But look at the bottom line, and the picture inverts. PAT of ₹95.1 Cr eked out just 3.6% growth. That 27-point gap between revenue and profit growth is not accounting noise—it is the story of a quarter where scale masked margin trouble.

The margin collapse, explained

Three things clobbered profit. First, Q1 witnessed ₹200–₹300 Cr in inventory gains (from clearing backlog) that reversed entirely in Q2, erasing the cushion. Second, the acquisitions—PendraCare and Citieffe—are operating at 4–5% EBITDA margin, dragging consolidated performance. Third, raw-material costs and FX headwinds, despite 4–5% price hikes, are still biting. Gross margin expanded 111 bps to 70.1% on pricing and acquisition mix, but EBITDA margin tells the truth: 25.3% normalized—solid in isolation, but a comedown from the 27%–29% the standalone business would deliver clean.

Growth rate, %
011.52334.530.8Revenue3.6PAT27.2Gap
Revenue growth outpaced profit growth by 27 points, driven by inventory reversal, FX headwinds, and acquisition integration costs.

Claims on the call vs. what holds up

Management assertions graded against delivered numbers

Europe business organic growth 40% in Q2

Organic Q2 European revenue ~40%; driven by inventory normalization and 28–29 new customer adds in H1. Management notes opportunity set remains 'very large.'

Supported

Domestic business growing 22% in Q2, tracking 20% guidance

Domestic Q2 revenue ₹172 Cr, +22% YoY; H1 domestic ≈20%. On track with stated guidance.

Supported

Gross margin 70.1% in H1, expanding 111 bps YoY

H1 consolidated gross margin 70.1%, up 111 bps. Pricing and acquisition contribution offset FX and raw-material headwinds.

Supported

Renal business recovering well despite Chinese dumping

Q2 renal revenue ₹51 Cr, +20% YoY; anti-dumping case filed end-June, 4 months in pursuit. 'Few months' away from government action; single-use device mandate (DGHS Oct/Nov) expected tailwind.

Overstated (recovery contingent on relief)

PAT growth tracking revenue growth

PAT +3.6% YoY vs revenue +30.8%. Compressed by inventory reversal (Q1 gains lost), FX/raw-material costs, acquisition drag. Normalized EBITDA margin ~25.3%.

Contradicted

What changed on this call

  • Standalone EBITDA margin raised to 26–27.5% (from 25–27%)

  • International business inflection confirmed (Europe 40% organic, international 15% YoY in Q2)

  • Acquired business margin recovery extended to 3–5 years (vs. earlier implied near-term)

  • U.S. business now quantified: ₹15–25m over 3–5 years (from ₹7m current)

  • FX/raw-material headwind expected H2 FY27; normalization deferred

The street's view: FII exodus and drawdown context

The stock closed at ₹1620 on November 9, down 51.75% from its all-time high of ₹3357.8. It is below its 50-day average (₹1629.65) but above the 200-day (₹1544.38), leaving it in a narrow neutral band. RSI of 57.7 signals no oversold trigger. But the ownership picture is more telling: FII holdings have halved from 11.41% in FY26 Q1 to 5.57% in FY27 Q1—a 590 basis-point exodus—while DII has been steadily accumulating. This is a stock that foreign institutions have been trimming even as the company grew revenue 31%. The disconnect is stark: the market is not convinced that scale translates to earnings recovery.

The bull-bear ledger

  • Bull: Consolidated revenue 31% YoY (₹580.5 Cr) with domestic 22% and international 15%, both tracking guidance. Standalone margin guidance raised.

  • Bull: Europe organic growth 40% Q2; U.S. 510k approval in hand, 15+ pending approvals, 10+ in development. Three major European projects go live Q3–Q4.

  • Bull: Gross margin 70.1% up 111 bps despite raw-material inflation; pricing power evident (4–5% hikes offsetting cost). Renal business 1,250 cumulative machines sold; single-use mandate (DGHS Oct/Nov) to drive demand.

  • Bear: PAT grew only 3.6% YoY despite 31% revenue growth—margin compression, not scale leverage. Normalized EBITDA 25.3%, dragged by acquisitions at 4–5% margin (target 20%, 3–5 year path).

  • Bear: Inventory volatility (Q1 ₹200–300 Cr gains reversed in Q2) and FX/raw-material headwinds expected to persist into H2. Normalized gross margin guidance 68–69%, suggesting margin pressure ahead.

  • Bear: Middle East geopolitical risk: ~20% of prior revenue lost; ongoing logistics/freight cost inflation. PendraCare particularly exposed; margin recovery deferred to FY28–FY29.

  • Bear: FII ownership halved in 12 months (11.41% → 5.57%). Stock down 51.75% from ATH despite 31% revenue growth—market pricing in execution risk on margin recovery.

Risks, ranked by how much they should concern a holder

Margin recovery timeline extended; acquisition integration slower than expected

High

PendraCare/Citieffe at 4–5% EBITDA vs 20% target, now explicitly 3–5 years out. PAT growth lagging revenue suggests cost structure headwinds deeper than anticipated. Execution risk on margin expansion is the key debate.

Geopolitical: Middle East ~20% of prior revenue; West Asia war driving freight/logistics cost inflation

High

Direct P&L hit from lost revenue, plus ongoing material cost pressures. Pricing hikes (4–5%) only partially offsetting. Normalization timeline uncertain; could extend into FY28.

Inventory and cost structure volatility; normalized margin lower than historical

Medium

Q1 ₹200–300 Cr inventory gains reversed in Q2, depressing PAT 3.6%. Normalized EBITDA ~25.3%; management expects gross margin 68–69% full year vs prior ~70%+. Suggests structural margin pressure (FX, raw materials) not fully reversible.

Chinese dumping and renal anti-dumping case outcome uncertain

Medium

Renal growing 20% despite competition, but case relief timeline vague ('few months'). DGHS single-use device mandate (Oct/Nov) expected to help, but enforcement and impact timing unclear.

U.S. business: policy uncertainty post-election; 3–5 year path ambitious

Medium

Target ₹15–25m (3–5 years) from ₹7m current. 510k approval in hand, but 15+ pending and 10+ in development. New tariff/approval risks post-election. Management deferred clarity to next quarter.

FII exit continuing; stock down 51% from ATH despite revenue growth

Low-Medium

Foreign institutions have halved holdings. Suggests market pricing in margin recovery risk or valuation rerating. Stock may find support at lower levels if execution falters further.

The debate

What to watch next

  • 1 · Q3 FY27 EBITDA margin and PAT growth

    Can Poly deliver normalized EBITDA margins of 26–27% standalone (vs 25.3% Q2) without inventory one-offs? PAT growth should accelerate above 3.6% if cost normalization is real. This is the acid test for the margin recovery narrative.

  • 2 · European project ramp and new customer quality

    Management booked three European projects (Q1, Q4 FY27, Q1 FY28 go-live). Visibility and profitability of these contracts will show whether 40% Q2 growth is sustainable or inventory-driven. New customer count (28–29 added in H1) should translate to recurring revenue.

  • 3 · Geopolitical relief or persistence; freight cost normalization

    Middle East revenue recovery timeline and freight cost trends will signal whether H2 margin recovery is achievable. Management expects normalization by H2 FY27; verify in Q3 guidance and commentary.

The number to track

From Q3 onwards, watch standalone EBITDA margin. It is the true test of Poly's operational execution. If it lands at 26–27% as guided, the margin recovery narrative holds and the FY28 upside begins. If it stalls below 25%, cost headwinds are deeper and the acquisition drag will take longer to shed. That single metric—not revenue, not PAT—will resolve whether Poly is a margin-recovery play or a mark-to-market surprise waiting to happen.

Poly Medicure is a steady executor with real international scale and positioning. But this quarter is not a step-change; it is a stress-test on execution. Revenue is strong, but profit is lagging—and the market has already penalized the stock for the margin recovery risk. Standalone EBITDA guidance raised (to 26–27.5%) is the lone bright spot; if FY28 delivers on that promise, the 51% drawdown will look prescient. If not, margin recovery will slide further into FY29–FY30, and valuation has little margin for disappointment.

Informational and educational content only. Not investment advice.